In trials Keytruda showed ‘meaningful efficacy’ with an objective response rate of 34%

Around 4,000 men newly diagnosed with high-risk metastatic hormone-sensitive prostate cancer would have been eligible for treatment with […]

The £3.2-million study will investigate whether there are any genetic causes of ME

NICE says the cost-effectiveness of the drug is uncertain, but Novartis says the decision denies patients access to […]

The drug is the first to be recommended as a treatment for the virus in the EU

Chiasma secures FDA approval for acromegaly pill Mycapssa years after near-catastrophic rejection kblankenship Fri, 06/26/2020 – 12:49

Chasing GW’s Epidiolex, Zogenix finally wins FDA nod for rare childhood epilepsy drug Fintepla aliu Fri, 06/26/2020 – […]

‘No presents anymore’: Inside Novartis’ scheme to boost Lucentis sales in Greece esagonowsky Fri, 06/26/2020 – 10:31

Novartis gives up on Xiidra’s EU approval, endangering payoff from $3.4B Takeda buyout aliu Fri, 06/26/2020 – 09:58

AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful kblankenship Fri, 06/26/2020 – 08:07